Global Active Pharmaceutical Ingredient (API) Market – Analysis By Drug Type (Generic, Innovative), Synthesis (Synthetic, Biotech), By Application, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)
Executive Summary
The global Active Pharmaceutical Ingredients (API) Market was valued at USD 179.6 Billion in the year 2020. Growth opportunities for the Active Pharmaceutical Ingredient market is attributed to the growth of the geriatric population, rising technical advancements, increasing API manufacturing facilities in the world and increasing number of research and development activities by some of the key market players in the global platform.
Additionally, growing awareness, as well as investments in the development of new drugs in the market, is pushing the number of clinical trials in the world which is driving the Active Pharmaceutical Ingredient market. With the rising prevalence of respiratory diseases due to the outbreak of COVID-19, it is expected that there will be more demand for new drugs which is likely to push the demand for API and consequently affect the Global Active Pharmaceutical Market in the world.
The biopharma companies are opting for mergers and acquisitions to gain access to new technologies, expand their market area and increase their capital for clinical trials and investments. The API market has been witnessing impressive growth over the past few years. This growth trend is projected to continue due to the increase in demand from the Asia Pacific region in the future. This is mainly driven by China, India and Japan which consist of a huge population and thereby huge incidence of infectious diseases which require medicines for treatment.
Furthermore, the rising death toll and spread of the virus prompted many pharmaceutical companies, biopharmaceutical companies and small start-ups to collaborate and bring out effective medicine to fight the same. Scientists all over the world found molecules that can effectively target COVID-19. Currently, 155 molecules are under clinical investigation, and 45 molecules are under preclinical development to be targeted against COVID-19. Companies monitored locally to protect the safety of study participants, staff and employees during such times.
Scope of the Report
The global Active Pharmaceutical Ingredients (API) Market was valued at USD 179.6 Billion in the year 2020. Growth opportunities for the Active Pharmaceutical Ingredient market is attributed to the growth of the geriatric population, rising technical advancements, increasing API manufacturing facilities in the world and increasing number of research and development activities by some of the key market players in the global platform.
Additionally, growing awareness, as well as investments in the development of new drugs in the market, is pushing the number of clinical trials in the world which is driving the Active Pharmaceutical Ingredient market. With the rising prevalence of respiratory diseases due to the outbreak of COVID-19, it is expected that there will be more demand for new drugs which is likely to push the demand for API and consequently affect the Global Active Pharmaceutical Market in the world.
The biopharma companies are opting for mergers and acquisitions to gain access to new technologies, expand their market area and increase their capital for clinical trials and investments. The API market has been witnessing impressive growth over the past few years. This growth trend is projected to continue due to the increase in demand from the Asia Pacific region in the future. This is mainly driven by China, India and Japan which consist of a huge population and thereby huge incidence of infectious diseases which require medicines for treatment.
Furthermore, the rising death toll and spread of the virus prompted many pharmaceutical companies, biopharmaceutical companies and small start-ups to collaborate and bring out effective medicine to fight the same. Scientists all over the world found molecules that can effectively target COVID-19. Currently, 155 molecules are under clinical investigation, and 45 molecules are under preclinical development to be targeted against COVID-19. Companies monitored locally to protect the safety of study participants, staff and employees during such times.
Scope of the Report
- The report analyses the Active Pharmaceutical Ingredients Market by Value (USD Billion)
- The report analyses the Active Pharmaceutical Ingredients Market by Application (Oncology, Cardiology, Diabetes, Neurology, Others).
- The report analyses the Active Pharmaceutical Ingredients Market by Drug Type (Generic API, Innovative API)
- The report analyses the Active Pharmaceutical Ingredients Market by Synthesis (Synthetic, Biotech)
- The Global Active Pharmaceutical Ingredients Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA).
- The Global Active Pharmaceutical Ingredients Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Italy, Spain, China, Japan, India).
- The attractiveness of the market has been presented by region, by Application, by Drug Type and by Synthesis.
- Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
- The companies analysed in the report include Pfizer Inc., GlaxoSmithKline, AbbVie Inc., Novartis AG, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sanofi, Bristol-Myers Squibb and Boehringer Ingelheim.
- The report presents the analysis of the Active Pharmaceutical Ingredients market for the historical period of 2016-2020 and the forecast period of 2021-2026.
- Active Pharmaceutical Ingredients Manufacturers
- Pharmaceutical Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
1. REPORT SCOPE AND METHODOLOGY
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET: PRODUCT OUTLOOK
4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET: SIZE AND FORECAST
4.1 Global Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026
5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET SEGMENTATION – BY APPLICATION, BY DRUG TYPE, BY SYNTHESIS
5.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Application
5.1.1 Oncology – Market Size and Forecast (2016-2026)
5.1.2 Cardiology– Market Size and Forecast (2016-2026)
5.1.3 Diabetes – Market Size and Forecast (2016-2026)
5.1.4 Neurology – Market Size and Forecast (2016-2026)
5.1.5 Others – Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Drug Type
5.2.1 Generic API– Market Size and Forecast (2016-2026)
5.2.2 Innovative API – Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Synthesis
5.3.1 Synthetic – Market Size and Forecast (2016-2026)
5.3.2 Biotech – Market Size and Forecast (2016-2026)
6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Region
7. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENT MARKET: AN ANALYSIS (2016-2026)
7.1 North America Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026)
7.2 North America Active Pharmaceutical Ingredient Market – Prominent Companies
7.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)
7.4 Market Segmentation By Drug Type (Generic API and Innovative API)
7.5 Market Segmentation By Synthesis (Synthetic and Biotech)
7.6 North America Active Pharmaceutical Ingredient Market: Country Analysis
7.7 Market Opportunity Chart of North America Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Active Pharmaceutical Ingredient Market: By Country
7.9 United States Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
7.10 United States Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
7.11 Canada Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
7.12 Canada Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8. EUROPE ACTIVE PHARMACEUTICAL INGREDIENT MARKET: AN ANALYSIS (2016-2026)
8.1 Europe Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.2 Europe Active Pharmaceutical Ingredient Market – Prominent Companies
8.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)
8.4 Market Segmentation By Drug Type (Generic API and Innovative API)
8.5 Market Segmentation By Synthesis (Synthetic and Biotech)
8.6 Europe Active Pharmaceutical Ingredient Market: Country Analysis
8.7 Market Opportunity Chart of Europe Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Active Pharmaceutical Ingredient Market: By Country
8.9 Germany Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.10 Germany Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.11 United Kingdom Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.13 France Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.14 France Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.15 Spain Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.16 Spain Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.17 Italy Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.18 Italy Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
9. ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENT MARKET: AN ANALYSIS (2016-2026)
9.1 Asia Pacific Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Active Pharmaceutical Ingredient Market – Prominent Companies
9.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)
9.4 Market Segmentation By Drug Type (Generic API and Innovative API)
9.5 Market Segmentation By Synthesis (Synthetic and Biotech)
9.6 Asia Pacific Active Pharmaceutical Ingredient Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Active Pharmaceutical Ingredient Market: By Country
9.9 China Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.10 China Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
9.11 Japan Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.12 Japan Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
9.13 India Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.14 India Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET DYNAMICS
10.1 Drivers
10.2 Restraints
10.3 Trends
11. MARKET ATTRACTIVENESS
11.1 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market – By Application, 2026
11.2 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Drug Type, 2026
11.3 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Synthesis, 2026
11.4 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Region, 2026
12. COMPETITIVE LANDSCAPE
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Market Share Analysis
13. COMPANY ANALYSIS
13.1 Pfizer Inc.,
13.2 GlaxoSmithKline
13.3 AbbVie Inc.
13.4 Novartis AG
13.5 Eli Lilly and Company
13.6 Merck KGaA
13.7 Teva Pharmaceutical Industries Ltd.
13.8 Sanofi
13.9 Bristol-Myers Squibb
13.10 Boehringer Ingelheim
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET: PRODUCT OUTLOOK
4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET: SIZE AND FORECAST
4.1 Global Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026
5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET SEGMENTATION – BY APPLICATION, BY DRUG TYPE, BY SYNTHESIS
5.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Application
5.1.1 Oncology – Market Size and Forecast (2016-2026)
5.1.2 Cardiology– Market Size and Forecast (2016-2026)
5.1.3 Diabetes – Market Size and Forecast (2016-2026)
5.1.4 Neurology – Market Size and Forecast (2016-2026)
5.1.5 Others – Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Drug Type
5.2.1 Generic API– Market Size and Forecast (2016-2026)
5.2.2 Innovative API – Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Synthesis
5.3.1 Synthetic – Market Size and Forecast (2016-2026)
5.3.2 Biotech – Market Size and Forecast (2016-2026)
6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Active Pharmaceutical Ingredient Market: By Region
7. NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENT MARKET: AN ANALYSIS (2016-2026)
7.1 North America Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026)
7.2 North America Active Pharmaceutical Ingredient Market – Prominent Companies
7.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)
7.4 Market Segmentation By Drug Type (Generic API and Innovative API)
7.5 Market Segmentation By Synthesis (Synthetic and Biotech)
7.6 North America Active Pharmaceutical Ingredient Market: Country Analysis
7.7 Market Opportunity Chart of North America Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
7.8 Competitive Scenario of North America Active Pharmaceutical Ingredient Market: By Country
7.9 United States Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
7.10 United States Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
7.11 Canada Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
7.12 Canada Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8. EUROPE ACTIVE PHARMACEUTICAL INGREDIENT MARKET: AN ANALYSIS (2016-2026)
8.1 Europe Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.2 Europe Active Pharmaceutical Ingredient Market – Prominent Companies
8.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)
8.4 Market Segmentation By Drug Type (Generic API and Innovative API)
8.5 Market Segmentation By Synthesis (Synthetic and Biotech)
8.6 Europe Active Pharmaceutical Ingredient Market: Country Analysis
8.7 Market Opportunity Chart of Europe Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
8.8 Competitive Scenario of Europe Active Pharmaceutical Ingredient Market: By Country
8.9 Germany Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.10 Germany Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.11 United Kingdom Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.12 United Kingdom Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.13 France Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.14 France Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.15 Spain Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.16 Spain Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
8.17 Italy Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
8.18 Italy Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
9. ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENT MARKET: AN ANALYSIS (2016-2026)
9.1 Asia Pacific Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Active Pharmaceutical Ingredient Market – Prominent Companies
9.3 Market Segmentation By Application (Oncology, Cardiology, Diabetes, Neurology and Others)
9.4 Market Segmentation By Drug Type (Generic API and Innovative API)
9.5 Market Segmentation By Synthesis (Synthetic and Biotech)
9.6 Asia Pacific Active Pharmaceutical Ingredient Market: Country Analysis
9.7 Market Opportunity Chart of Asia Pacific Active Pharmaceutical Ingredient Market - By Country, By Value, 2026
9.8 Competitive Scenario of Asia Pacific Active Pharmaceutical Ingredient Market: By Country
9.9 China Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.10 China Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
9.11 Japan Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.12 Japan Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
9.13 India Active Pharmaceutical Ingredient Market: Size and Forecast (2016-2026), By Value
9.14 India Active Pharmaceutical Ingredient Market Segmentation - By Application, By Drug Type, By Synthesis (2016-2026)
10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT MARKET DYNAMICS
10.1 Drivers
10.2 Restraints
10.3 Trends
11. MARKET ATTRACTIVENESS
11.1 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market – By Application, 2026
11.2 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Drug Type, 2026
11.3 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Synthesis, 2026
11.4 Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market - By Region, 2026
12. COMPETITIVE LANDSCAPE
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Market Share Analysis
13. COMPANY ANALYSIS
13.1 Pfizer Inc.,
13.2 GlaxoSmithKline
13.3 AbbVie Inc.
13.4 Novartis AG
13.5 Eli Lilly and Company
13.6 Merck KGaA
13.7 Teva Pharmaceutical Industries Ltd.
13.8 Sanofi
13.9 Bristol-Myers Squibb
13.10 Boehringer Ingelheim
TABLES AND FIGURES
Figure 1: Global Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 2: Percentage of API manufacturing facilities for all drugs (August 2019)
Figure 3: World’s leading causes of death (in millions), 2019
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Estimated number of new cases in 2020, worldwide, both sexes, all ages
Figure 7: Global Active Pharmaceutical Ingredient Market-By Application Market Share, 2020 & 2026
Figure 8: Global Active Pharmaceutical Ingredient Market- By Oncology, By Value (USD Billion), 2016-2026
Figure 9: Global Active Pharmaceutical Ingredient Market- By Cardiology, By Value (USD Billion), 2016-2026
Figure 10: Global Active Pharmaceutical Ingredient Market- By Diabetes, By Value (USD Billion), 2016-2026
Figure 11: Global Active Pharmaceutical Ingredient Market- By Neurology, By Value (USD Billion), 2016-2026
Figure 12: Global Active Pharmaceutical Ingredient Market- By Others, By Value (USD Billion), 2016-2026
Figure 13: Global Active Pharmaceutical Ingredient Market- By Drug Type Market Share, 2020 & 2026
Figure 14: Global Active Pharmaceutical Ingredient Market- By Generic API, By Value (USD Billion), 2016-2026
Figure 15: Global Active Pharmaceutical Ingredient Market- By Innovative API, By Value (USD Billion), 2016-2026
Figure 16: Global Active Pharmaceutical Ingredient Market- By Synthesis Market Share, 2020 & 2026
Figure 17: Global Active Pharmaceutical Ingredient Market- By Synthetic, By Value (USD Billion), 2016-2026
Figure 18: Global Active Pharmaceutical Ingredient Market- By Biotech, By Value (USD Billion), 2016-2026
Figure 19: Global Active Pharmaceutical Ingredient Market- By Region Market Share, 2020 & 2026
Figure 20: North America Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 21: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 22: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 23: North America Urban population, 2015-2018 (In %)
Figure 24: North America Active Pharmaceutical Ingredient players market share (%), 2020
Figure 25: North America Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 26: North America Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 27: North America Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 28: Market Opportunity Chart of North America Active Pharmaceutical Ingredient Market- By Country, By Value (Year 2016-2026)
Figure 29: North America Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026
Figure 30: United States Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 31: United State year-on-year growth of Active Pharmaceutical Ingredient (in %), (2017-2026)
Figure 32: United State population aged 65 and above, (in % of total population), 2016-2020
Figure 33: United State health expenditure (% of GDP), 2013-2018
Figure 34: United State Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 35: United State Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 36: United State Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 37: Canada Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 38: Canada population aged 65 and above (% of total population), 2016-2020
Figure 39: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 40: Canada Urban population, 2015-2019 (In %)
Figure 41: Canada Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 42: Canada Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 43: Canada Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 44: Europe Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 45: Europe current health expenditure (% of GDP), (2014-2018)
Figure 46: Europe population aged 65 and above (% of total population), 2020
Figure 47: Europe percentage of dying between age 30 to 70 from any cardiovascular disease, cancer, diabetes and chronic respiratory disease, 2019
Figure 48: Europe Active Pharmaceutical Ingredient players market share (%), 2020
Figure 49: Europe Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 50: Europe Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 51: Europe Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 52: Market Opportunity Chart of Europe Active Pharmaceutical Ingredient Market- By Country, By Value (Year 2016-2026)
Figure 53: Europe Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026
Figure 54: Germany Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 55: Germany current health expenditure (% of GDP), (2014-2018)
Figure 56: Germany population aged 65 and above (% of total population), 2016-2020
Figure 57: Germany urban population (% of total population), 2016-2019
Figure 58: Germany Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 59: Germany Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 60: Germany Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 61: United Kingdom Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 62: United Kingdom current health expenditure (% of GDP), (2014-2018)
Figure 63: United Kingdom population aged 65 and above (% of total population), 2016-2020
Figure 64: United Kingdom urban population (in millions), 2016-2020
Figure 65: United Kingdom Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 66: United Kingdom Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 67: United Kingdom Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 68: France Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 69: France current health expenditure (% of GDP), (2014-2018)
Figure 70: France urban population (% of total population), 2016-2020
Figure 71: France population aged 65 and above (% of total population), 2016-2020
Figure 72: France Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 73: France Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 74: France Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 75: Spain Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 76: Spain current health expenditure (% of GDP), (2014-2018)
Figure 77: Spain population aged 65 and above (% of total population), 2016-2020
Figure 78: Spain urban population (% of total population), 2016-2020
Figure 79: Spain Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 80: Spain Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 81: Spain Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 82: Italy Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 83: Italy current health expenditure (% of GDP), (2014-2018)
Figure 84: Italy population aged 65 and above (% of total population), 2016-2020
Figure 85: Italy urban population (% of total population), 2016-2020
Figure 86: Italy Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 87: Italy Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 88: Italy Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 89: Asia Pacific Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 90: Asia Pacific urban population (% of total population), 2016-2020
Figure 91: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 92: Asia Pacific population aged 65 years and above (% of total population), 2016-2020
Figure 93: Asia Pacific Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 94: Asia Pacific Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 95: Asia Pacific Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 96: Market Opportunity Chart of APAC Active Pharmaceutical Ingredient Market- By Country, By Value (Year-2026)
Figure 97: APAC Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026
Figure 98: China Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 99: China total population in billions, 2016-2020
Figure 100: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 101: China export destinations of Active Pharmaceutical Ingredient, 2019
Figure 102: China Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 103: China Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 104: China Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 105: Japan Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 106: Japan population above 65 years (% of total population), 2016-2020
Figure 107: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 108: Japan urban population (in millions), 2016-2020
Figure 109: Japan Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 110: Japan Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 111: Japan Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 112: India Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 113: India Current Healthcare Expenditure (% of GDP), 2015-2018
Figure 114: India population (in billions), 2016-2020
Figure 115: India urban population (% of total population), 2015-2019
Figure 116: India Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 117: India Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 118: India Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Million), 2016-2026
Figure 119: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Application (Year-2016-2026)
Figure 120: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Drug Type (Year 2016-2026)
Figure 121: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Synthesis (Year 2016-2026)
Figure 122: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Region (Year 2016-2026)
Figure 123: Global Active Pharmaceutical Ingredient players market share (%), 2020
Figure 124: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Figure 125: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Figure 126: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
Figure 127: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 128: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
Figure 129: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 130: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 131: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Figure 132: AbbVie Inc. Net Income (USD Million), 2016-2020
Figure 133: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 134: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 135: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 136: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 137: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 138: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 139: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Figure 140: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Figure 141: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 142: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Figure 143: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 144: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 145: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 146: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 147: Teva Pharmaceutical Industries Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 148: Teva Pharmaceutical Industries Ltd. Net Income, 2016-2020 (USD Million)
Figure 149: Teva Pharmaceutical Industries Ltd. sales Revenues, By Business Segment (%) in North America, FY2020
Figure 150: Teva Pharmaceutical Industries Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 151: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 152: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 153: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 154: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 155: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 156: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 157: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 158: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
Figure 159: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)
Figure 160: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)
Figure 161: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020
Figure 162: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020
Figure 1: Global Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 2: Percentage of API manufacturing facilities for all drugs (August 2019)
Figure 3: World’s leading causes of death (in millions), 2019
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Estimated number of new cases in 2020, worldwide, both sexes, all ages
Figure 7: Global Active Pharmaceutical Ingredient Market-By Application Market Share, 2020 & 2026
Figure 8: Global Active Pharmaceutical Ingredient Market- By Oncology, By Value (USD Billion), 2016-2026
Figure 9: Global Active Pharmaceutical Ingredient Market- By Cardiology, By Value (USD Billion), 2016-2026
Figure 10: Global Active Pharmaceutical Ingredient Market- By Diabetes, By Value (USD Billion), 2016-2026
Figure 11: Global Active Pharmaceutical Ingredient Market- By Neurology, By Value (USD Billion), 2016-2026
Figure 12: Global Active Pharmaceutical Ingredient Market- By Others, By Value (USD Billion), 2016-2026
Figure 13: Global Active Pharmaceutical Ingredient Market- By Drug Type Market Share, 2020 & 2026
Figure 14: Global Active Pharmaceutical Ingredient Market- By Generic API, By Value (USD Billion), 2016-2026
Figure 15: Global Active Pharmaceutical Ingredient Market- By Innovative API, By Value (USD Billion), 2016-2026
Figure 16: Global Active Pharmaceutical Ingredient Market- By Synthesis Market Share, 2020 & 2026
Figure 17: Global Active Pharmaceutical Ingredient Market- By Synthetic, By Value (USD Billion), 2016-2026
Figure 18: Global Active Pharmaceutical Ingredient Market- By Biotech, By Value (USD Billion), 2016-2026
Figure 19: Global Active Pharmaceutical Ingredient Market- By Region Market Share, 2020 & 2026
Figure 20: North America Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 21: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 22: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 23: North America Urban population, 2015-2018 (In %)
Figure 24: North America Active Pharmaceutical Ingredient players market share (%), 2020
Figure 25: North America Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 26: North America Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 27: North America Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 28: Market Opportunity Chart of North America Active Pharmaceutical Ingredient Market- By Country, By Value (Year 2016-2026)
Figure 29: North America Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026
Figure 30: United States Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 31: United State year-on-year growth of Active Pharmaceutical Ingredient (in %), (2017-2026)
Figure 32: United State population aged 65 and above, (in % of total population), 2016-2020
Figure 33: United State health expenditure (% of GDP), 2013-2018
Figure 34: United State Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 35: United State Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 36: United State Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 37: Canada Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 38: Canada population aged 65 and above (% of total population), 2016-2020
Figure 39: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 40: Canada Urban population, 2015-2019 (In %)
Figure 41: Canada Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 42: Canada Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 43: Canada Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 44: Europe Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 45: Europe current health expenditure (% of GDP), (2014-2018)
Figure 46: Europe population aged 65 and above (% of total population), 2020
Figure 47: Europe percentage of dying between age 30 to 70 from any cardiovascular disease, cancer, diabetes and chronic respiratory disease, 2019
Figure 48: Europe Active Pharmaceutical Ingredient players market share (%), 2020
Figure 49: Europe Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 50: Europe Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 51: Europe Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 52: Market Opportunity Chart of Europe Active Pharmaceutical Ingredient Market- By Country, By Value (Year 2016-2026)
Figure 53: Europe Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026
Figure 54: Germany Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 55: Germany current health expenditure (% of GDP), (2014-2018)
Figure 56: Germany population aged 65 and above (% of total population), 2016-2020
Figure 57: Germany urban population (% of total population), 2016-2019
Figure 58: Germany Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 59: Germany Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 60: Germany Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 61: United Kingdom Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 62: United Kingdom current health expenditure (% of GDP), (2014-2018)
Figure 63: United Kingdom population aged 65 and above (% of total population), 2016-2020
Figure 64: United Kingdom urban population (in millions), 2016-2020
Figure 65: United Kingdom Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 66: United Kingdom Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 67: United Kingdom Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 68: France Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 69: France current health expenditure (% of GDP), (2014-2018)
Figure 70: France urban population (% of total population), 2016-2020
Figure 71: France population aged 65 and above (% of total population), 2016-2020
Figure 72: France Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 73: France Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 74: France Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 75: Spain Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 76: Spain current health expenditure (% of GDP), (2014-2018)
Figure 77: Spain population aged 65 and above (% of total population), 2016-2020
Figure 78: Spain urban population (% of total population), 2016-2020
Figure 79: Spain Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 80: Spain Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 81: Spain Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 82: Italy Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 83: Italy current health expenditure (% of GDP), (2014-2018)
Figure 84: Italy population aged 65 and above (% of total population), 2016-2020
Figure 85: Italy urban population (% of total population), 2016-2020
Figure 86: Italy Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 87: Italy Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 88: Italy Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 89: Asia Pacific Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 90: Asia Pacific urban population (% of total population), 2016-2020
Figure 91: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 92: Asia Pacific population aged 65 years and above (% of total population), 2016-2020
Figure 93: Asia Pacific Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 94: Asia Pacific Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 95: Asia Pacific Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 96: Market Opportunity Chart of APAC Active Pharmaceutical Ingredient Market- By Country, By Value (Year-2026)
Figure 97: APAC Active Pharmaceutical Ingredient Market- By Country Market Share, 2020 & 2026
Figure 98: China Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 99: China total population in billions, 2016-2020
Figure 100: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 101: China export destinations of Active Pharmaceutical Ingredient, 2019
Figure 102: China Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 103: China Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 104: China Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 105: Japan Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 106: Japan population above 65 years (% of total population), 2016-2020
Figure 107: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 108: Japan urban population (in millions), 2016-2020
Figure 109: Japan Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 110: Japan Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 111: Japan Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Billion), 2016-2026
Figure 112: India Active Pharmaceutical Ingredient Market Size, By Value, 2016-2026 (USD Billion)
Figure 113: India Current Healthcare Expenditure (% of GDP), 2015-2018
Figure 114: India population (in billions), 2016-2020
Figure 115: India urban population (% of total population), 2015-2019
Figure 116: India Active Pharmaceutical Ingredient Market- By Application, By Value (USD Billion), 2016-2026
Figure 117: India Active Pharmaceutical Ingredient Market- Drug Type, By Value (USD Billion), 2016-2026
Figure 118: India Active Pharmaceutical Ingredient Market- By Synthesis, By Value (USD Million), 2016-2026
Figure 119: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Application (Year-2016-2026)
Figure 120: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Drug Type (Year 2016-2026)
Figure 121: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Synthesis (Year 2016-2026)
Figure 122: Market Attractiveness Chart of Global Active Pharmaceutical Ingredient Market- By Region (Year 2016-2026)
Figure 123: Global Active Pharmaceutical Ingredient players market share (%), 2020
Figure 124: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Figure 125: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Figure 126: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
Figure 127: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 128: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
Figure 129: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 130: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 131: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Figure 132: AbbVie Inc. Net Income (USD Million), 2016-2020
Figure 133: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 134: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 135: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 136: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 137: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 138: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 139: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Figure 140: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Figure 141: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 142: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Figure 143: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 144: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 145: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 146: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 147: Teva Pharmaceutical Industries Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 148: Teva Pharmaceutical Industries Ltd. Net Income, 2016-2020 (USD Million)
Figure 149: Teva Pharmaceutical Industries Ltd. sales Revenues, By Business Segment (%) in North America, FY2020
Figure 150: Teva Pharmaceutical Industries Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 151: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 152: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 153: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 154: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 155: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 156: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 157: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 158: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
Figure 159: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)
Figure 160: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)
Figure 161: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020
Figure 162: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020
